George Elston
Direttore Finanziario/CFO presso EYEPOINT PHARMACEUTICALS, INC.
Patrimonio netto: 508 511 $ in data 31/05/2024
Profilo
George O.
Elston has founded Chatham Street Partners in 2010.
He is currently working as an Independent Trustee at db-X ETF Trust since 2010 and as the Chief Financial Officer & Executive Vice President at EyePoint Pharmaceuticals, Inc. since 2019.
Previously, he held positions such as President & Chief Executive Officer at Enzyvant, Inc. from 2018 to 2019, President & Chief Executive Officer at Oncology Venture US, Inc. from 2017 to 2018, and Director at AVANT Immunotherapeutics, Inc. in 2008.
He also served as an Independent Director at Celldex Therapeutics, Inc. from 2008 to 2017.
Additionally, he has held various other positions including Director at Celldex Therapeutics, Inc., Principal at C.
R.
Bard, Inc. (New Jersey), Chief Financial Officer, Secretary & Treasurer at Catalent JNP, Inc. from 2014 to 2016, Vice President-Finance at Elusys Therapeutics, Inc. from 2000 to 2009, Chief Financial Officer & Senior Vice President at KBI Biopharma, Inc. from 2013 to 2014, Chief Operating & Financial Officer at Optherion, Inc. from 2008 to 2010, and Chief Financial Officer at Enzyvant Therapeutics, Inc. from 2018 to 2019.
He also has a degree from Pace University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 25/05/2024 | 47 480 ( 0.09% ) | 508 511 $ | 31/05/2024 |
Posizioni attive di George Elston
| Società | Posizione | Inizio |
|---|---|---|
| EYEPOINT PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 14/11/2019 |
| db-X ETF Trust | Direttore/Membro del Consiglio | 01/10/2010 |
Precedenti posizioni note di George Elston
| Società | Posizione | Fine |
|---|---|---|
Enzyvant Therapeutics, Inc.
 Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA. | Direttore Finanziario/CFO | 01/09/2019 |
Enzyvant, Inc.
 Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Amministratore Delegato | 01/09/2019 |
Oncology Venture US, Inc.
 Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Amministratore Delegato | 01/10/2018 |
| CELLDEX THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 15/06/2017 |
| JUNIPER PHARMACEUTICALS INC | Direttore Finanziario/CFO | 31/12/2016 |
Formazione di George Elston
| Pace University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CELLDEX THERAPEUTICS, INC. | Health Services |
| EYEPOINT PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 15 |
|---|---|
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
Celldex Research Corp.
 Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Commercial Services |
Celldex Therapeutics, Inc. (Old)
 Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
C. R. Bard, Inc. (New Jersey)
 C. R. Bard, Inc. (New Jersey) Medical SpecialtiesHealth Technology C. R. Bard, Inc. engages in designing, development, manufacturing, packaging, distribution, and sales of medical, surgical, diagnostic, and patient care devices. It sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. The company was founded by Charles Russell Bard in 1907 and is headquartered in Franklin Lakes, NJ. | Health Technology |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Optherion, Inc.
 Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | Health Technology |
| Trillium USA, Inc. | Utilities |
| Pricewaterhousecoopers LLC | |
| Chatham Street Partners | |
Catalent JNP, Inc.
 Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
| db-X ETF Trust | Miscellaneous |
KBI Biopharma, Inc.
 KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Commercial Services |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Oncology Venture US, Inc.
Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Commercial Services |
Enzyvant Therapeutics, Inc.
Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- George Elston
